RESUMEN
The African parasite Trypanosoma brucei gambiense accounts for 97% of human sleeping sickness cases. T. b. gambiense resists the specific human innate immunity acting against several other tsetse-fly-transmitted trypanosome species such as T. b. brucei, the causative agent of nagana disease in cattle. Human immunity to some African trypanosomes is due to two serum complexes designated trypanolytic factors (TLF-1 and -2), which both contain haptoglobin-related protein (HPR) and apolipoprotein LI (APOL1). Whereas HPR association with haemoglobin (Hb) allows TLF-1 binding and uptake via the trypanosome receptor TbHpHbR (ref. 5), TLF-2 enters trypanosomes independently of TbHpHbR (refs 4, 5). APOL1 kills trypanosomes after insertion into endosomal/lysosomal membranes. Here we report that T. b. gambiense resists TLFs via a hydrophobic ß-sheet of the T. b. gambiense-specific glycoprotein (TgsGP), which prevents APOL1 toxicity and induces stiffening of membranes upon interaction with lipids. Two additional features contribute to resistance to TLFs: reduction of sensitivity to APOL1 requiring cysteine protease activity, and TbHpHbR inactivation due to a L210S substitution. According to such a multifactorial defence mechanism, transgenic expression of T. b. brucei TbHpHbR in T. b. gambiense did not cause parasite lysis in normal human serum. However, these transgenic parasites were killed in hypohaptoglobinaemic serum, after high TLF-1 uptake in the absence of haptoglobin (Hp) that competes for Hb and receptor binding. TbHpHbR inactivation preventing high APOL1 loading in hypohaptoglobinaemic serum may have evolved because of the overlapping endemic area of T. b. gambiense infection and malaria, the main cause of haemolysis-induced hypohaptoglobinaemia in western and central Africa.
Asunto(s)
Apolipoproteínas/sangre , Apolipoproteínas/metabolismo , Lipoproteínas HDL/sangre , Lipoproteínas HDL/metabolismo , Trypanosoma brucei gambiense/fisiología , África , Animales , Animales Modificados Genéticamente , Apolipoproteína L1 , Apolipoproteínas/antagonistas & inhibidores , Apolipoproteínas/toxicidad , Membrana Celular/química , Membrana Celular/metabolismo , Proteasas de Cisteína/metabolismo , Haptoglobinas/metabolismo , Hemoglobinas/metabolismo , Hemólisis , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Metabolismo de los Lípidos , Lipoproteínas HDL/antagonistas & inhibidores , Lipoproteínas HDL/química , Lipoproteínas HDL/toxicidad , Parásitos/patogenicidad , Parásitos/fisiología , Estructura Secundaria de Proteína , Suero/química , Suero/parasitología , Trypanosoma brucei gambiense/efectos de los fármacos , Trypanosoma brucei gambiense/patogenicidad , Tripanosomiasis Africana/parasitología , Glicoproteínas Variantes de Superficie de Trypanosoma/química , Glicoproteínas Variantes de Superficie de Trypanosoma/metabolismoRESUMEN
The protozoan parasite Trypanosoma brucei is lysed by apolipoprotein L-I, a component of human high-density lipoprotein (HDL) particles that are also characterized by the presence of haptoglobin-related protein. We report that this process is mediated by a parasite glycoprotein receptor, which binds the haptoglobin-hemoglobin complex with high affinity for the uptake and incorporation of heme into intracellular hemoproteins. In mice, this receptor was required for optimal parasite growth and the resistance of parasites to the oxidative burst by host macrophages. In humans, the trypanosome receptor also recognized the complex between hemoglobin and haptoglobin-related protein, which explains its ability to capture trypanolytic HDLs. Thus, in humans the presence of haptoglobin-related protein has diverted the function of the trypanosome haptoglobin-hemoglobin receptor to elicit innate host immunity against the parasite.
Asunto(s)
Receptores de Superficie Celular/inmunología , Trypanosoma brucei brucei/inmunología , Secuencia de Aminoácidos , Animales , Haptoglobinas/metabolismo , Hemoglobinas/metabolismo , Humanos , Inmunidad Innata , Lipoproteínas HDL/metabolismo , Ratones , Ratones Endogámicos , Datos de Secuencia Molecular , Receptores de Superficie Celular/metabolismoRESUMEN
Humans have innate immunity against Trypanosoma brucei brucei that is known to involve apolipoprotein L-I (APOL1). Recently, a case of T. evansi infection in a human was identified in India. We investigated whether the APOL1 pathway was involved in this occurrence. The serum of the infected patient was found to have no trypanolytic activity, and the finding was linked to the lack of APOL1, which was due to frameshift mutations in both APOL1 alleles. Trypanolytic activity was restored by the addition of recombinant APOL1. The lack of APOL1 explained the patient's infection with T. evansi.
Asunto(s)
Apolipoproteínas/deficiencia , Apolipoproteínas/genética , Mutación del Sistema de Lectura , Lipoproteínas HDL/deficiencia , Lipoproteínas HDL/genética , Trypanosoma , Tripanosomiasis/genética , Secuencia de Aminoácidos , Animales , Apolipoproteína L1 , Apolipoproteínas/uso terapéutico , Humanos , Lipoproteínas HDL/uso terapéutico , Masculino , Datos de Secuencia Molecular , Proteínas Recombinantes/uso terapéutico , Trypanosoma/aislamiento & purificación , Tripanosomiasis/tratamiento farmacológicoRESUMEN
Apolipoprotein L-I is the trypanolytic factor of human serum. Here we show that this protein contains a membrane pore-forming domain functionally similar to that of bacterial colicins, flanked by a membrane-addressing domain. In lipid bilayer membranes, apolipoprotein L-I formed anion channels. In Trypanosoma brucei, apolipoprotein L-I was targeted to the lysosomal membrane and triggered depolarization of this membrane, continuous influx of chloride, and subsequent osmotic swelling of the lysosome until the trypanosome lysed.
Asunto(s)
Apolipoproteínas/química , Apolipoproteínas/metabolismo , Membranas Intracelulares/metabolismo , Lipoproteínas HDL/química , Lipoproteínas HDL/metabolismo , Lisosomas/metabolismo , Trypanosoma brucei brucei/metabolismo , Ácido 4,4'-Diisotiocianostilbeno-2,2'-Disulfónico/farmacología , Secuencia de Aminoácidos , Animales , Aniones/metabolismo , Apolipoproteína L1 , Apolipoproteínas/genética , Apolipoproteínas/farmacología , Células Inmovilizadas , Cloruros/metabolismo , Colicinas/química , Colicinas/farmacología , Escherichia coli/efectos de los fármacos , Escherichia coli/crecimiento & desarrollo , Humanos , Membranas Intracelulares/efectos de los fármacos , Membranas Intracelulares/ultraestructura , Canales Iónicos/metabolismo , Membrana Dobles de Lípidos/química , Lipoproteínas HDL/genética , Lipoproteínas HDL/farmacología , Lisosomas/efectos de los fármacos , Lisosomas/ultraestructura , Modelos Moleculares , Datos de Secuencia Molecular , Mutación , Permeabilidad , Conformación Proteica , Estructura Secundaria de Proteína , Estructura Terciaria de Proteína , Proteínas Recombinantes/metabolismo , Trypanosoma brucei brucei/efectos de los fármacos , Trypanosoma brucei brucei/ultraestructuraRESUMEN
Transcription of the variant surface glycoprotein (VSG) gene of Trypanosoma brucei occurs in a single of multiple polycistronic expression sites (ESs). Analysis of RNA from proliferative long slender (LS) bloodstream forms demonstrated that initiation of transcription occurs in different ESs, but inefficient RNA processing and elongation is linked to RNA polymerase arrest in all except one unit at a time. The pattern of ES transcripts was analysed during the transformation of dividing LS forms into quiescent short stumpy (SS) forms. The results demonstrated that the mono-allelic control allowing preferential RNA production from a given ES stops during this process. Accordingly, the steady-state ES transcripts, particularly the VSG mRNA, were strongly reduced. However, transcripts from the beginning of different ESs were still synthesized, and in vitro run-on transcription analysis indicated that RNA polymerase was still fully associated with the promoter-proximal half of the 'active' ES. Analysis of transcripts from two central tandem genes confirmed the existence of a residual decreasing transcriptional gradient in the 'active' ES of SS forms. Thus, in these forms the RNA polymerase of the ES is inactivated in situ. This inactivation is accompanied by a strong overall reduction of nuclear DNA transcription. Although cAMP is involved in the LS to SS transformation, no direct effect of cAMP was observed on the VSG ES control.
Asunto(s)
Variación Antigénica , Regulación de la Expresión Génica , Genes Protozoarios , Transcripción Genética , Trypanosoma brucei brucei/genética , Glicoproteínas Variantes de Superficie de Trypanosoma/genética , Alelos , Animales , Secuencia de Bases , ADN Protozoario/genética , Datos de Secuencia Molecular , ARN Mensajero/genética , ARN Mensajero/aislamiento & purificación , ARN Mensajero/metabolismo , ARN Protozoario/genética , ARN Protozoario/metabolismo , Trypanosoma brucei brucei/crecimiento & desarrollo , Tripanosomiasis Africana/parasitologíaRESUMEN
Human sleeping sickness in east Africa is caused by the parasite Trypanosoma brucei rhodesiense. The basis of this pathology is the resistance of these parasites to lysis by normal human serum (NHS). Resistance to NHS is conferred by a gene that encodes a truncated form of the variant surface glycoprotein termed serum resistance associated protein (SRA). We show that SRA is a lysosomal protein, and that the amino-terminal alpha-helix of SRA is responsible for resistance to NHS. This domain interacts strongly with a carboxy-terminal alpha-helix of the human-specific serum protein apolipoprotein L-I (apoL-I). Depleting NHS of apoL-I, by incubation with SRA or anti-apoL-I, led to the complete loss of trypanolytic activity. Addition of native or recombinant apoL-I either to apoL-I-depleted NHS or to fetal calf serum induced lysis of NHS-sensitive, but not NHS-resistant, trypanosomes. Confocal microscopy demonstrated that apoL-I is taken up through the endocytic pathway into the lysosome. We propose that apoL-I is the trypanosome lytic factor of NHS, and that SRA confers resistance to lysis by interaction with apoL-I in the lysosome.